Core Viewpoint - A class action securities lawsuit has been filed against Dow Inc. alleging securities fraud that negatively impacted investors between January 30, 2025, and July 23, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Dow Inc. overstated its ability to manage macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [2]. - It is alleged that the true extent of negative impacts from competitive pressures, declining global sales, and product oversupply was understated [2]. - Defendants' public statements are claimed to have been materially false and misleading throughout the relevant period [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until October 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against WPP plc, alleging securities fraud that negatively impacted investors between February 27, 2025, and July 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that WPP's management made overly positive statements while concealing significant adverse facts about the company's media arm, which was struggling to cope with macroeconomic challenges and losing market share [2]. - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing this to macroeconomic uncertainties and weaker-than-expected new business, partly due to ongoing restructuring efforts [2]. - Following the trading update, WPP's stock price dropped from $35.82 per share on July 8, 2025, to $29.34 per share on July 9, 2025, marking an approximate decline of 18.1% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified period have until December 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - V.F. Corporation is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between October 30, 2023, and May 20, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that V.F. Corporation made materially false and misleading statements regarding its turnaround plans, particularly concerning the Vans brand, which required significant reset actions to return to growth [2]. - Following the release of V.F. Corporation's fiscal 2025 results on May 21, 2025, it was revealed that Vans' revenue growth had significantly declined, with losses worsening from 8% to 20% in the fourth quarter [2]. - The company attributed its disappointing results to deliberate actions taken to eliminate unprofitable businesses, indicating that even without these actions, Vans would have experienced a high single-digit revenue decline [2]. Group 2: Stock Price Impact - On May 21, 2025, V.F. Corporation's stock price dropped from $14.43 to $12.15 per share, marking a decline of approximately 15.8% in one day following the negative news [2]. Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until November 12, 2025, to request appointment as lead plaintiff in the lawsuit, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 4: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Core Points - A class action lawsuit has been filed against Marex Group Plc for alleged securities fraud and unlawful business practices [2][4] - The lawsuit follows a report by NINGI Research that accused Marex of engaging in a multi-year accounting scheme to conceal losses and inflate profits [4] - Marex's stock price dropped by 6.19% to $35.31 per share following the release of the NINGI Research report [4] Summary by Sections Class Action Details - Investors are advised to contact Pomerantz LLP if they purchased Marex securities during the Class Period [1] - The deadline to apply as Lead Plaintiff is December 8, 2025 [2] Allegations Against Marex - NINGI Research's report claims Marex has used opaque off-balance-sheet entities and fictitious transactions to mislead investors [4] - The report suggests that Marex's financials are unreliable and that the company is a "financial house of cards" [4] Company Background - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for class members [5]

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging securities fraud and unlawful business practices related to the company's New Drug Application for aficamten [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Cytokinetics and certain officers or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until November 17, 2025, to request to be appointed as Lead Plaintiff if they purchased Cytokinetics securities during the Class Period [2]. Group 2: FDA Interaction and Stock Impact - On March 10, 2025, Cytokinetics disclosed that the FDA would not convene an advisory committee meeting for aficamten's NDA [4]. - The FDA extended the action date for aficamten's NDA from September 26, 2025, to December 26, 2025, due to the need for a Risk Evaluation and Mitigation Strategy (REMS) that was not included in the original NDA [4]. - Following the news, Cytokinetics' stock price fell by $5.57 per share (12.98%) to close at $37.35 on May 2, 2025 [5]. - On May 6, 2025, CEO Robert I. Blum acknowledged that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS [5]. - After this acknowledgment, the stock price fell by $2.70 per share (7.36%) to close at $33.97 on May 6, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Molina Healthcare, Inc. regarding allegations of securities fraud and unlawful business practices [2][4]. Financial Performance - On July 7, 2025, Molina reported second quarter adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - Molina cut its full-year 2025 adjusted earnings per share guidance by 10.2% at the midpoint, revising it from at least $24.50 per share to a range of $21.50 to $22.50 per share [4]. - Following this announcement, Molina's stock price fell by $6.97 per share, or 2.9%, closing at $232.61 per share [4]. Subsequent Guidance Cuts - On July 23, 2025, Molina further reduced its full-year 2025 earnings guidance, now expecting adjusted earnings to be no less than $19.00 per diluted share, representing a 13.6% cut from the previous guidance [5]. - The company's GAAP net income for the second quarter was reported at $4.75 per diluted share, an 8% decrease year over year [5]. - Molina also cut its full-year 2025 GAAP net income guidance by 27% to $912 million, attributing the results to a challenging medical cost trend environment [5]. - Following this announcement, Molina's stock price dropped by $32.03 per share, or 16.84%, closing at $158.22 per share [5].

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Lantheus and certain o ...

Core Viewpoint - Purcell & Lefkowitz LLP is investigating 374Water Inc. to determine if the company's directors breached their fiduciary duties related to recent corporate actions [1]. Group 1 - The investigation is being conducted on behalf of 374Water Inc.'s shareholders [1]. - Shareholders interested in more information about their rights and options can contact Purcell & Lefkowitz LLP [2]. - The law firm specializes in representing shareholders affected by securities fraud and breaches of fiduciary duty [3].

Core Viewpoint - A securities class action lawsuit has been filed against Fortinet, Inc. for allegedly making false and misleading statements regarding its business operations and product refresh cycle during the class period from November 8, 2024, to August 6, 2025 [1][2]. Allegations Against Fortinet - The lawsuit claims that Fortinet misrepresented the profitability of its product refresh cycle, stating it would be more lucrative than it actually was, as it involved older products that constituted a "small percentage" of the company's business [2]. - It is alleged that Fortinet did not have a clear understanding of the actual number of FortiGate firewalls eligible for upgrades, which misled investors about the company's operational capabilities [2]. - The company reportedly misled investors by claiming that the refresh would gain momentum over two years, while in reality, it pushed through about half of the refresh in just a few months by the end of the second quarter of 2025 [2]. - As a result of these actions, the statements made by Fortinet regarding its business, operations, and future prospects were deemed materially false and misleading [2]. Lead Plaintiff Process - Investors in Fortinet have until November 21, 2025, to seek appointment as a lead plaintiff representative in the class action lawsuit, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case and is responsible for selecting legal counsel to represent the class [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and certain executives violated the Securities Exchange Act of 1934, impacting investors who purchased or acquired its common stock [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's primary drug candidate is sonelokimab (SLK), aimed at treating hidradenitis suppurativa (HS) [3]. Allegations - The lawsuit claims that during the class period, MoonLake made false or misleading statements and failed to disclose critical information regarding SLK's efficacy compared to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for HS [4]. - Specific allegations include that SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F), and that SLK's unique Nanobody structure does not provide a clinical advantage over BIMZELX [4]. Stock Performance Impact - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, which indicated SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - Investors who suffered substantial losses and wish to serve as lead plaintiff in the class action lawsuit must file motions by December 15, 2025 [2][6]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [7].